IRWD vs MHD Comparison

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Blackrock Muniholdings Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes. The fund mainly invests its managed assets in municipal bonds rated investment grade or, if unrated, are deemed to be of comparable quality by the investment adviser at the time of investment. Its investment portfolio is mainly comprised of long-term municipal bonds with a maturity of more than ten years at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.